165 related articles for article (PubMed ID: 7969342)
1. Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency.
Finkelstein JS; Klibanski A; Schaefer EH; Hornstein MD; Schiff I; Neer RM
N Engl J Med; 1994 Dec; 331(24):1618-23. PubMed ID: 7969342
[TBL] [Abstract][Full Text] [Related]
2. Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial.
Finkelstein JS; Klibanski A; Arnold AL; Toth TL; Hornstein MD; Neer RM
JAMA; 1998 Sep 23-30; 280(12):1067-73. PubMed ID: 9757854
[TBL] [Abstract][Full Text] [Related]
3. Increases in bone mineral density after discontinuation of daily human parathyroid hormone and gonadotropin-releasing hormone analog administration in women with endometriosis.
Finkelstein JS; Arnold AL
J Clin Endocrinol Metab; 1999 Apr; 84(4):1214-9. PubMed ID: 10199756
[TBL] [Abstract][Full Text] [Related]
4. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
Lane NE; Sanchez S; Modin GW; Genant HK; Pierini E; Arnaud CD
J Bone Miner Res; 2000 May; 15(5):944-51. PubMed ID: 10804025
[TBL] [Abstract][Full Text] [Related]
5. Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.
Cosman F; Nieves J; Woelfert L; Formica C; Gordon S; Shen V; Lindsay R
J Bone Miner Res; 2001 May; 16(5):925-31. PubMed ID: 11341338
[TBL] [Abstract][Full Text] [Related]
6. Skeletal effects of parathyroid hormone infusion in ovariectomized rats with or without estrogen repletion.
Shen V; Birchman R; Wu DD; Lindsay R
J Bone Miner Res; 2000 Apr; 15(4):740-6. PubMed ID: 10780865
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
[TBL] [Abstract][Full Text] [Related]
8. Daily and cyclic parathyroid hormone in women receiving alendronate.
Cosman F; Nieves J; Zion M; Woelfert L; Luckey M; Lindsay R
N Engl J Med; 2005 Aug; 353(6):566-75. PubMed ID: 16093465
[TBL] [Abstract][Full Text] [Related]
9. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?
Riis BJ; Christiansen C; Johansen JS; Jacobson J
J Clin Endocrinol Metab; 1990 Apr; 70(4):920-4. PubMed ID: 2138631
[TBL] [Abstract][Full Text] [Related]
10. The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy.
Leather AT; Studd JW; Watson NR; Holland EF
Obstet Gynecol; 1993 Jan; 81(1):104-7. PubMed ID: 8416441
[TBL] [Abstract][Full Text] [Related]
11. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.
Smith MR; McGovern FJ; Zietman AL; Fallon MA; Hayden DL; Schoenfeld DA; Kantoff PW; Finkelstein JS
N Engl J Med; 2001 Sep; 345(13):948-55. PubMed ID: 11575286
[TBL] [Abstract][Full Text] [Related]
12. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Brodowska A
Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
[TBL] [Abstract][Full Text] [Related]
13. Alendronate prevents further bone loss in renal transplant recipients.
Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
[TBL] [Abstract][Full Text] [Related]
14. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
15. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
[TBL] [Abstract][Full Text] [Related]
16. Preexisting bone loss associated with ovariectomy in rats is reversed by parathyroid hormone.
Liu CC; Kalu DN; Salerno E; Echon R; Hollis BW; Ray M
J Bone Miner Res; 1991 Oct; 6(10):1071-80. PubMed ID: 1796755
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
[TBL] [Abstract][Full Text] [Related]
18. Magnesium deficiency and bone loss after cardiac transplantation.
Boncimino K; McMahon DJ; Addesso V; Bilezikian JP; Shane E
J Bone Miner Res; 1999 Feb; 14(2):295-303. PubMed ID: 9933485
[TBL] [Abstract][Full Text] [Related]
19. Effect of calcium supplementation on bone loss in postmenopausal women.
Reid IR; Ames RW; Evans MC; Gamble GD; Sharpe SJ
N Engl J Med; 1993 Feb; 328(7):460-4. PubMed ID: 8421475
[TBL] [Abstract][Full Text] [Related]
20. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
Mitlak BH; Burdette-Miller P; Schoenfeld D; Neer RM
J Bone Miner Res; 1996 Apr; 11(4):430-9. PubMed ID: 8992873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
